4DMedical Limited (ASX:4DX) Secures $22.6M Through Option Exercises
4DMedical (ASX:4DX) raises $22.6 million through option exercises, enhancing its cash position to $45.5 million for strategic growth.
Category: Healthcare
Race Oncology (ASX:RAC) Discovers RCDS1 Mechanism of Action
Race Oncology (ASX:RAC) announces the discovery of RCDS1’s primary anticancer mechanism, enhancing its clinical and commercial potential.
Bio-Gene Technology Limited (ASX:BGT) Announces Positive Flavocide Efficacy Results
Bio-Gene Technology Limited (ASX:BGT) reports over 90% tick mortality with Flavocide, driving an 87% increase in its stock price.
Starpharma (ASX:SPL) Partners with Radiopharm Theranostics to Develop Radiotherapy Asset
Starpharma (ASX:SPL) announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset.
Micro-X Ltd (ASX:MX1) Awarded $4.4M Grant for Ambulance Head CT Trials
Micro-X Ltd (ASX:MX1) secures a $4.4M grant to trial its innovative Head CT device in ambulances, enhancing stroke diagnosis and treatment.
Proteomics International Laboratories Ltd (ASX: PIQ) Announces Board and Management Transition
Proteomics International (ASX: PIQ) announces the retirement of Managing Director Dr Richard Lipscombe and the search for his successor.
Optiscan Imaging Limited (ASX:OIL) Announces Entitlement Issue to Raise $17.75 Million
Optiscan Imaging Limited (ASX:OIL) announces a $17.75 million entitlement issue to fund clinical studies and regulatory approvals.
Starpharma (ASX:SPL) Releases FY25 Financial Results
Starpharma (ASX:SPL) reports a 183% revenue increase and reduced losses in its FY25 financial results.
Telix Pharmaceuticals (ASX:TLX) Reports H1 2025 Financial Results
Telix Pharmaceuticals (ASX:TLX) reports a 63% revenue increase in H1 2025, emphasizing strong growth and strategic investments for future expansion.
Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Plaque Module
Artrya Limited (ASX:AYA) receives FDA clearance for Salix® Coronary Plaque module, expanding its U.S. commercial opportunities.